Walgreens, Career Step partner to provide externships
PROVO, Utah — Pharmacy technician students at an online school will be able to perform externships with a major retail pharmacy chain, under a partnership the two companies announced.
Career Step said it would partner with Walgreens to allow students to work at local Walgreens stores after gaining a solid foundation of pharmacy technician knowledge in the program. Externship will typically consist of 180 practical hours.
"These externships are a phenomenal opportunity for our students," Career Step pharmacy technician instructor Rebekah Hutchins said. "The Career Step pharmacy technician training program already incorporates a variety of teaching methods — including video, simulations and interactive exercises — and now these externships are adding hands-on experience in the real world for our students to thoroughly learn the material and prepare for certification and employment."
U.K.-based pharmacy chain teams with U.S. digital health products provider to improve adherence
REDWOOD CITY, Calif. — British retail pharmacy chain Lloyds Pharmacy and U.S.-based Proteus Biochemical are collaborating to launch a digital health product that combines sensor-enabled tablets, a sensor patch and a mobile health application to help people with complex medication regimens and health issues.
The two companies announced Friday that they would work together to commercialize and launch Helius, which they said would provide "assurance and peace of mind" to patients and their families, friends and providers, and improve medication adherence.
"Lloyds Pharmacy is committed to improving positive health outcomes for patients, and the Helius system is an exciting development, which takes our current medication adherence offering to a whole new level," Lloyds Pharmacy healthcare services director Steve Gray said. "There is a huge problem with medicines not being taken correctly. Anyone taking several medications shows how easy it can be to lose track of whether or not you’ve taken the correct tablets that day."
Bristol-Myers Squibb commences tender offer for Inhibitex
NEW YORK — Bristol-Myers Squibb has officially launched its tender offer for Inhibitex, the drug maker said Friday.
Bristol said it had commenced a $2.5 billion offer to buy all outstanding shares of Inhibitex, an Alpharetta, Ga.-based company developing treatments for hepatitis C. The company’s leading product is INX-189, an orally administered drug currently in phase-2 clinical trials.
Bristol announced its intention to buy Inhibitex Monday. The New York-based drug maker said it would make Inhibitex a wholly owned subsidiary following the acquisition.